Approval · Notice of Compliance 18323 · 2016
SUMATRIPTAN: Notice of Compliance 18323
Issued August 2, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18323
- Date
- August 2, 2016
- Company
- Pro Doc LimiteeLaval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Admin
- Reason
- Product monograph update to match the innovator's product monograph
- Canadian reference product
- IMITREX DF (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SUMATRIPTAN | 02324652 | Marketed |
| SUMATRIPTAN | 02324660 | Marketed |
Medicinal ingredients
- SUMATRIPTAN SUCCINATE 50 MG per TAB
- SUMATRIPTAN SUCCINATE 100 MG per TAB